Notify me when Pivotal bioVenture Partners Fund I, L.P. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OCS | Oculis Holding AG | Ordinary Shares, CHF 0.01 par value per share | 4.9% | $49.9M | 2.82M | Nan Fung Group Holdings Limited | Sep 30, 2025 | ||
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | 0 | Pivotal bioVenture Partners Fund I, L.P. | Jul 1, 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Date Filed |
|---|